EUTROPICS PHARMACEUTICALS, INC.

Address

60 GRAMPIAM WAY
DORCHESTER, MA, 02125-

Information

DUNS: 604131859
# of Employees: 0

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Development of Praedicare Dx as CDx for AML Period of Performance: September 19, 2014 through September 18, 2015

    Amount: $1,499,743.00

    Not Available

    SBIRPhase II2014Department of Health and Human Services
  2. IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)

    Amount: $199,892.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and ...

    SBIRPhase I2012Department of Health and Human Services
  3. IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA

    Amount: $1,499,746.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unn ...

    SBIRPhase II2012Department of Health and Human Services
  4. BH3 Profiling as a Companion Diagnostic For Velcade

    Amount: $199,860.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve ...

    SBIRPhase I2010Department of Health and Human Services
  5. Development of small molecule inhibitor of Mcl-1 for cancer treatment

    Amount: $1,357,720.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1 (Mcl-1), a member of this protein family, is a key regul ...

    SBIRPhase II2010Department of Health and Human Services
  6. Development of small molecule inhibitors of Mcl-1 for cancer treament

    Amount: $326,983.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1(Mcl-1), a member of this protein family, is a key regu ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government